Details of the Drug Combinations

General Information of This Drug (ID: DMNB4XK)

• Drug Name: BVD-523 (DMNB4XK)

Indication

Melanoma; ICD 11: 2C30; Status: Phase 2 [1]; Solid tumour/cancer; ICD 11: 2A00-2F9Z; Status: Phase 1/2 [2]; Pancreatic cancer; ICD 11: 2C10; Status: Phase 1 [3]

List of Combinatorial Drugs (CBD) Containing This Drug

2 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
BVD-523 + Panobinostat	DC9I5SP	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
BVD-523 + Marizomib	DCF7EI4	Marizomib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]

2 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
BVD-523 + Hydroxychloroquine	DCSQZU4	Hydroxychloroquine	Gastrointestinal Neoplasms	[5]
BVD-523 + Hydroxychloroquine	DCW0FZX	Hydroxychloroquine	Tumor, Solid	[6]

References

• [1] ClinicalTrials.gov (NCT03417739) A Phase II Study of BVD-523 in Metastatic Uveal Melanoma. U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT01781429) Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies. U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [5] ClinicalTrials.gov (NCT04145297) Ulixertinib (BVD-523) and Hydroxychloroquine in Patients w Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas
• [6] ClinicalTrials.gov (NCT05221320) Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies